ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents?
Is a combination of anti-angiogenic with EFGR TKI a new standard
Date
23 Sep 2020Session
ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents?Presenters
Martin ReckAuthors
M. ReckAuthor affiliations
- Thoracic Oncology Dept., Krankenhaus Grosshansdorf, 22927 - Grosshansdorf/DE
Resources
Resources from the same session
Is Osimertinib the best single agent if 1st line?
Presenter: Myung-Ju Ahn
Session: ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents?
Resources:
Slides
Webcast
Should chemotherapy be combined upfront with EGFR TKI?
Presenter: Ross Soo
Session: ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents?
Resources:
Slides
Webcast
Do immune check point work in EGFR TKI?
Presenter: Edward Garon
Session: ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents?
Resources:
Slides
Webcast
In a multiline setting, what is the best sequencing?
Presenter: Enriqueta Felip
Session: ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents?
Resources:
Slides
Webcast
Conclusions
Presenter: Myung-Ju Ahn
Session: ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents?
Resources:
Slides
Webcast
Live Q&A
Presenter: Martin Reck
Session: ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents?
Resources:
Webcast
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.